Novel RUNX1 isoforms determine the fate of acute myeloid leukemia cells by controlling CD56 expression

Blood

Volumn 110, Issue 6, 2007, Pages 2027-2033

  Gattenloehner, Stefan ^a   Chuvpilo, Sergei ^a   Langebrake, Claudia ^b   Reinhardt, Dirk ^b   Müller Hermelink, Hans Konrad ^a   Serfling, Edgar ^a   Vincent, Angela ^c   Marx, Alexander ^d  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b University Childrens Hospital Hannover   (Germany)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; CD56 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL 2; PROTEIN P30; PROTEIN SUBUNIT; TRANSCRIPTION FACTOR RUNX1;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CELL FATE; CONTROLLED STUDY; HUMAN; HUMAN CELL; LEUKEMIA CELL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TRANSCRIPTION INITIATION;

EID: 34548857895     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-02-074203     Document Type: Article

References (31)

1. Crossin KL, Krushel LA. Cellular signaling by neural cell adhesion molecules of the immunoglobulin superfamily. Dev Dyn. 2000;218:260-279.
2. Edelman GM, Jones FS. Gene regulation of cell adhesion: a key step in neural morphogenesis. Brain Res Brain Res Rev. 1998;26:337-352.
3. Jin L, Hemperly JJ, Lloyd RV. Expression of neural cell adhesion molecule in normal and neoplastic human neuroendocrine tissues. Am J Pathol. 1991;138:961-969.
4. Orth JM, McGuinness MP, Qiu J, Jester WF Jr, Li LH. Use of in vitro systems to study male germ cell development in neonatal rats. Theriogenology. 1998;49:431-439.
5. Raspadori D, Damiani D, Lenoci M, et al. CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clinical prognosis. Leukemia. 2001;15:1161-1164.
6. Itoh S, Sugawara T, Enomoto S, et al. Clonal evolution of blasts in an elderly patient with CD56(+) relapsed acute promyelocytic leukemia. Am J Hematol. 2002;69:59-63.
7. Baer MR, Stewart CC, Lawrence D, et al. Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22; q22). Blood. 1997;90:1643-1648.
8. Daniels JT, Davis BJ, Houde-McGrail L, Byrd JC. Clonal selection of CD56+ t(8;21) AML blasts: further suggestion of the adverse clinical significance of this biologic marker? Br J Haematol. 1999;107:381-383.
9. Gattenlohner S, Waller C, Ertl G, Bultmann BD, Muller-Hermelink HK, Marx A. NCAM(CD56) and RUNX1(AML1) are up-regulated in human ischemic cardiomyopathy and a rat model of chronic cardiac ischemia. Am J Pathol. 2003;163:1081-1090.
10. Yamagata T, Maki K, Mitani K. Runx1/AML1 in normal and abnormal hematopoiesis. Int J Hematol. 2005;82:1-8.
11. Gattenlohner S, Schneider C, Thamer C, et al. Expression of foetal type acetylcholine receptor is restricted to type 1 muscle fibres in human neuromuscular disorders. Brain. 2002;125:1309-1319.
12. Chuvpilo S, Zimmer M, Kerstan A, et al. Alternative polyadenylation events contribute to the induction of NF-ATc in effector T cells. Immunity. 1999;10:261-269.
13. Levanon D, Glusman G, Bangsow T, et al. Architecture and anatomy of the genomic locus encoding the human leukemia-associated transcription factor RUNX1/AML1. Gene. 2001;262:23-33.
14. Zhang L, Lukasik SM, Speck NA, Bushweller JH. Structural and functional characterization of Runx1, CBF beta, and CBF beta-SMMHC. Blood Cells Mol Dis. 2003;30:147-156.
15. Otto F, Lubbert M, Stock M. Upstream and downstream targets of RUNX proteins. J Cell Biochem. 2003;89:9-18.
16. Krushel LA, Cunningham BA, Edelman GM, Crossin KL. NF-kappaB activity is induced by neural cell adhesion molecule binding to neurons and astrocytes. J Biol Chem. 1999;274:2432-2439.
17. Kobori M, Yang Z, Gong D, et al. Wedelolactone suppresses LPS-induced caspase-11 expression by directly inhibiting the IKK complex. Cell Death Differ. 2004;11:123-130.
18. Yang DH, Lee JJ, Mun YC, et al. Predictable prognostic factor of CD56 expression in patients with acute myeloid leukemia with t(8:21) after high dose cytarabine or allogeneic hematopoietic stem cell transplantation.Am J Hematol. 2007;82:1-5.
19. Rhoades KL, Hetherington CJ, Rowley JD, et al. Synergistic up-regulation of the myeloid-specific promoter for the macrophage colony-stimulating factor receptor by AML1 and the t(8;21) fusion protein may contribute to leukemogenesis. Proc Natl Acad Sci U S A. 1996;93:11895-11900.
20. Fang X, Liu Z, Fan Y, et al. Switch to full-length of XAF1 mRNA expression in prostate cancer cells by the DNA methylation inhibitor. Int J Cancer. 2006;118:2485-2489.
21. Xu Q, Lee C. Discovery of novel splice forms and functional analysis of cancer-specific alternative splicing in human expressed sequences. Nucleic Acids Res. 2003;31:5635-5643.
22. Hayes GM, Carrigan PE, Beck AM, Miller LJ. Targeting the RNA splicing machinery as a novel treatment strategy for pancreatic carcinoma. Cancer Res. 2006;66:3819-3827.
23. Kaiser U, Jaques G, Havemann K, Auerbach B. Serum NCAM: a potential new prognostic marker for multiple myeloma. Blood. 1994;83:871-873.
24. Onodera H, Nagayama S, Tachibana T, Fujimoto A, Imamura M. Brain metastasis from colorectal cancer. Int J Colorectal Dis. 2005;20:57-61.
25. Daniel L, Bouvier C, Chetaille B, et al. Neural cell adhesion molecule expression in renal cell carcinomas: relation to metastatic behavior. Hum Pathol. 2003;34:528-532.
26. Blake J, Ziman MR. Aberrant PAX3 and PAX7 expression. A link to the metastatic potential of embryonal rhabdomyosarcoma and cutaneous malignant melanoma? Histol Histopathol. 2003;18:529-539.
27. Abbott JJ, Amirkhan RH, Hoang MP. Malignant melanoma with a rhabdoid phenotype: histologic, immunohistochemical, and ultrastructural study of a case and review of the literature. Arch Pathol Lab Med. 2004;128:686-688.
28. Bielekova B, Catalfamo M, Reichert-Scrivner S, et al. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (Daclizumab) in multiple sclerosis. Proc Natl Acad Sci U S A. 2006;103:5941-5946.
29. Vargas F, Tolosa E, Sospedra M, et al. Characterization of neural cell adhesion molecule (NCAM) expression in thyroid follicular cells: induction by cytokines and over-expression in autoimmune glands. Clin Exp Immunol. 1994;98:478-488.
30. Takahashi K, Aranami T, Endoh M, Miyake S, Yamamura T. The regulatory role of natural killer cells in multiple sclerosis. Brain. 2004;127:1917-1927.
31. Zhou FQ, Zhong J, Snider WD. Extracellular crosstalk: when GDNF meets N-CAM. Cell. 2003;113:814-815.